The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.
 
Dan Feng
No Relationships to Disclose
 
Laura Collins
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
 
Margaret K. Callahan
Employment - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Celgene (I); Kleo Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Immunocore; Merck; Moderna Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Clinical Care Options; Potomac Center for Medical Education
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Sophie Piperno-Neumann
Consulting or Advisory Role - Immunocore; Pierre Fabre
Research Funding - Foghorn Therapeutics (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Novartis; PharmaMar
 
Paul D. Nathan
Consulting or Advisory Role - 4SC; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD; Novartis
Research Funding - Immunocore (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore; MSD
 
Jessica Cecile Hassel
Honoraria - Amgen; BMS GmbH & Co. KG; Bristol Myers Squibb Foundation; GlaxoSmithKline; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - BMS GmbH & Co. KG (Inst); GlaxoSmithKline; Immunocore (Inst); MSD; Novartis (Inst); Onkowissen; Philogen (Inst); Pierre Fabre; Sanofi Aventis GmbH (Inst); Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); Idera (Inst); Immunocore (Inst); IO Biotech (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - 4SC; BMS GmbH & Co. KG; Iovance Biotherapeutics; Sun Pharma
 
Howard Goodall
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
 
Chris Holland
Employment - Immunocore
Stock and Other Ownership Interests - Amgen; Immunocore; MacroGenics
Patents, Royalties, Other Intellectual Property - Co-involvement in a patent for the compositions and methods for treating diffuse large B cell lymphoma
 
Koustubh Ranade
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Novartis
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); Immunocore; Linnaeus Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Polaris; Targovax (Inst); Xcovery
Patents, Royalties, Other Intellectual Property - UpToDate